Introduction
TNBC, tumor, mTNBC, Cancer
TUMOR, DISEASE, TRIPLE-NEGATIVE BREAST CANCER, TRIPLE NEGATIVE BREAST CANCER, CANCER
Metastatic triple-negative breast cancer (mTNBC), defined as lack of estrogen receptor (ER), progression receptor (PR), and human epidermal growth factor receptor 2 (HER2) overexpression, remains a disease of unmet need. This is largely attributed to tumor heterogeneity and chemotherapy resistance.The Cancer Genome Atlas data demonstrated that the most frequently altered genomic drivers in TNBC include the phosphatidylinositol 3-kinase-AKT-mTOR (PI3K-AKT-mTOR) signaling pathway.DNA–damaging agents such as platinum drugs are active in TNBC. The randomized Triple Negative Breast Cancer Trial (TNT) showed no overall response rate (ORR) difference between carboplatin and docetaxel in the overall population: 31.4% vs 34% (The Impassion130 study demonstrated the addition of atezolizumab (anti–PD-L1) to 